3-Cyclohexene-1-methanol, α,4-dimethyl-α-(4-methyl-3-penten-1-yl)-

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: scientifically acceptable study report

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1980

Report date:

1980

Materials and methods

Principles of method if other than guideline:

according to BASF-internal standard

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

(R*,R*)-α,4-dimethyl-α-(4-methyl-3-pentenyl)cyclohex-3-ene-1-methanol

EC Number:

208-205-9

EC Name:

(R*,R*)-α,4-dimethyl-α-(4-methyl-3-pentenyl)cyclohex-3-ene-1-methanol

Cas Number:

515-69-5

Molecular formula:

C15H26O

IUPAC Name:

6-methyl-2-(4-methylcyclohex-3-en-1-yl)hept-5-en-2-ol

Test material form:

other: liquid

Details on test material:

Name of the test substance used in the study report: (+-)-alpha-Bisabolol (liquid)

Test animals

Species:

mouse

Strain:

NMRI

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Fasting period before study: 15- 20 h before administration
- Diet: a standardized animal laboratory diet

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

CMC (carboxymethyl cellulose)

Details on exposure:

Form of administration; emulsion; 0.5% aqueous carboxymethyl cellulose with 1 - 2 drops of Cremophor EL
Concentrations used: 2, 4.64, 7 and 10%
Administration volume: 10 mL/kg

Doses:

200, 464, 700, 1000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

633 mg/kg bw

Mortality:

Male animals:
200 mg/kg: 0/5 D14;
464 mg/kg: 1/5 D14;
700 mg/kg: 5/5 D14;
1000 mg/kg: 5/5 D14;

Female animals:
200 mg/kg: 0/5 D14;
464 mg/kg: 1/5 D14;
700 mg/kg: 2/5 D14;
1000 mg/kg: 3/5 D14;

Clinical signs:

Dyspnea, apathy, abnormal position, staggering gait, trembling, stretching, rolling fits, ruffled fur, erythema, exsiccosis, fascicular twitching, ptosis, paresis, poor general state

Body weight:

Mean body weight male animals:
Dose group 200 mg/kg: 22 g at study start; 25.8 g at D13
Dose group 464 mg/kg: 26 g at study start; 30 g at D13
Dose group 700 mg/kg: 30 g at study start; 21.5 g at D7
Dose group 1000 mg/kg: 30 g at study start; 23.8 g at D2-4

Mean body weight female animals:
Dose group 200 mg/kg: 20 g at study start; 25.6 g at D13
Dose group 464 mg/kg: 24 g at study start; 26.3 g at D13
Dose group 700 mg/kg: 26 g at study start; 29.3 g at D7
Dose group 1000 mg/kg: 24 g at study start; 25 g at D2-4

Gross pathology:

Animals that died: No intraabdominal deposits of the test substance or adhesions.
Sacrificed animals: liver: intraabdominal adhesions; liver margins blunt; serosa adstringed